Literature DB >> 9399504

Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group.

M Wilson1, J S Remington, C Clavet, G Varney, C Press, D Ware.   

Abstract

As a result of reports received by the Food and Drug Administration (FDA) of false-positive results obtained with FDA-cleared in vitro diagnostic kits for the detection of Toxoplasma-specific human immunoglobulin M (IgM) antibodies, an FDA-sponsored evaluation of six kits was performed. A battery of 258 serum specimens, including 30 specimens drawn 1 to 5 months after initial Toxoplasma infection and 228 specimens from Toxoplasma IgG-positive individuals, Toxoplasma IgG-negative individuals, rheumatoid factor-positive persons, and persons determined to be Toxoplasma IgM positive by commercially available assays, was assembled, randomly assorted, and coded. The battery was tested at the FDA with six commercially available kits, at the Palo Alto Medical Foundation (PAMF) by the PAMF double-sandwich IgM enzyme-linked immunosorbent assay (PAMF IgM ELISA), and at the Centers for Disease Control and Prevention (CDC) by the CDC EIA IgM. The results of the PAMF IgM ELISA that were obtained with the battery were considered to be the "gold standard" for this study; specificity rates were computed by considering the PAMF results to be 100% specific. Sensitivity and specificity rates were found to be as follows: CDC EIA IgM, 100 and 99.1%, respectively; Abbott IMx Toxo IgM, version 1, 100 and 77.5%, respectively; Abbott IMx Toxo IgM, version 2, 93.3 and 97.3%, respectively; Abbott Toxo-M EIA, 100 and 84.2%, respectively; BioMérieux Vitek VIDAS Toxo IgM, 100 and 98.6%, respectively; BioWhittaker Toxocap-M, 100 and 95.9%, respectively; Gull Toxo IgM, 97 and 85.6%, respectively; and Sanofi Diagnostics Pasteur Platelia Toxo IgM, 100 and 96.8%, respectively. Although the extent of false-positive reactions with these kits cannot be calculated because the study was retrospective and sample choices were biased, the results may be useful as an indicator of the relative specificities of these kits.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399504      PMCID: PMC230132          DOI: 10.1128/jcm.35.12.3112-3115.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma).

Authors:  A B Sabin; H A Feldman
Journal:  Science       Date:  1948-12-10       Impact factor: 47.728

2.  False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test.

Authors:  O Liesenfeld; C Press; J G Montoya; R Gill; J L Isaac-Renton; K Hedman; J S Remington
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

3.  Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays.

Authors:  A Decoster; B Lecolier
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Evaluation of commercial serodiagnostic kits for toxoplasmosis.

Authors:  M Wilson; D A Ware; K W Walls
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

5.  Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis.

Authors:  O Liesenfeld; C Press; R Flanders; R Ramirez; J S Remington
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

6.  Epidemic toxoplasmosis associated with infected cats.

Authors:  S M Teutsch; D D Juranek; A Sulzer; J P Dubey; R K Sikes
Journal:  N Engl J Med       Date:  1979-03-29       Impact factor: 91.245

7.  Comparison of methods for quantitating antigen-specific immunoglobulin M antibody with a reverse enzyme-linked immunosorbent assay.

Authors:  J P Siegel; J S Remington
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

8.  An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis.

Authors:  Y Naot; J S Remington
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

9.  Multicenter evaluation of a new commercial assay for detection of immunoglobulin M antibodies to Toxoplasma gondii. Multicenter Study Group.

Authors:  V Luyasu; A R Robert; L Schaefer; J Macioszek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

10.  Reverse enzyme immunoassay for detection of specific anti-Toxoplasma immunoglobulin M antibodies.

Authors:  E L Franco; K W Walls; A J Sulzer
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

  10 in total
  47 in total

1.  Comparison of immulite with vidas for detection of infection in a low-prevalence population of pregnant women in The Netherlands.

Authors:  F Vlaspolder; P Singer; A Smit; R J Diepersloot
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  VIDAS test for avidity of Toxoplasma-specific immunoglobulin G for confirmatory testing of pregnant women.

Authors:  Jose G Montoya; Oliver Liesenfeld; Sandra Kinney; Cynthia Press; Jack S Remington
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

Review 3.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products.

Authors:  Elisa Beghetto; Andrea Spadoni; Luca Bruno; Wilma Buffolano; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Determination of tetanus antibodies by a double-antigen enzyme-linked immunosorbent assay in individuals of various age groups.

Authors:  K Caglar; R Karakus; C Aybay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

6.  Toxoplasmosis during pregnancy.

Authors:  Ariel Many; Gideon Koren
Journal:  Can Fam Physician       Date:  2006-01       Impact factor: 3.275

7.  Toxoplasma lymphadenitis mimicking malign axillary lymphadenopathy of a left breast mass.

Authors:  Ali Cihat Yildirim; Hasan Bostanci; Engin Deniz Yilmaz; Nizamettin Kutluer; Hulagu Kargici
Journal:  Updates Surg       Date:  2012-03-01

8.  Toxoplasma gondii-positive human sera recognise intracellular tachyzoites and bradyzoites with diverse patterns of immunoreactivity.

Authors:  Marijo S Roiko; Kaice LaFavers; Diane Leland; Gustavo Arrizabalaga
Journal:  Int J Parasitol       Date:  2017-11-21       Impact factor: 3.981

9.  Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women.

Authors:  Pierre Flori; Laetitia Tardy; Hugues Patural; Bahrie Bellete; Marie-Noëlle Varlet; Jamal Hafid; Hélène Raberin; Roger Tran Manh Sung
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 10.  Obstetrician-gynecologists and perinatal infections: a review of studies of the Collaborative Ambulatory Research Network (2005-2009).

Authors:  Meaghan A Leddy; Bernard Gonik; Jay Schulkin
Journal:  Infect Dis Obstet Gynecol       Date:  2010-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.